Current progress in neoantigen-based dendritic cell vaccines for solid tumors

Immunotherapy, particularly immune checkpoint inhibitors (ICIs) programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), has heralded a new era of tumor treatment. Although ICIs have clinical benefits, their complex heterogeneity and diverse...

Full description

Bibliographic Details
Published in:Cancer Biology & Medicine
Main Authors: Yuting Li, Abudukadierjiang Abudureheman, Jianming Xu
Format: Article
Language:English
Published: China Anti-Cancer Association 2025-10-01
Subjects:
neoantigen
dendritic cell
vaccines
immunotherapy
solid tumor
Online Access:https://www.cancerbiomed.org/content/22/10/1143

Internet

https://www.cancerbiomed.org/content/22/10/1143

Similar Items